Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Suspended 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 5Breast 5Thoracic 4Gastrointestinal 4Other hematologic neoplasm 2Head & Neck 2CNS 2Sarcoma 1Myeloid 1Lymphoid 1Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 440Precursor Cell Lymphoblastic Leukemia-Lymphoma 238Hematologic Neoplasms 216Leukemia, Lymphocytic, Chronic, B-Cell 186Myelodysplastic Syndromes 160Leukemia 129Lymphoma 91Lymphoma, Non-Hodgkin 82Leukemia, Myelogenous, Chronic, BCR-ABL Positive 73Multiple Myeloma 69Recurrence 59Leukemia, Myelomonocytic, Chronic 56Neoplasms 53Leukemia, Biphenotypic, Acute 48Burkitt Lymphoma 48Myeloproliferative Disorders 46Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 43Lymphoma, Large B-Cell, Diffuse 42Lymphoma, Mantle-Cell 41Hodgkin Disease 39Lymphoma, Follicular 34Lymphoma, B-Cell 33Lymphoma, B-Cell, Marginal Zone 27Waldenstrom Macroglobulinemia 26Leukemia, B-Cell 26Anemia, Refractory, with Excess of Blasts 25Primary Myelofibrosis 24Myelodysplastic-Myeloproliferative Diseases 21Leukemia, Myeloid, Chronic-Phase 19Hematologic Diseases 19

Interventions

venetoclax 1liposomal doxorubicin 1Taxes 1Paclitaxel 1Lomustine 1Irinotecan 1Gemcitabine 1Doxorubicin 1Carboplatin 1CA-4948 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × Other hematologic neoplasm × 90 days × Clear all
NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Actuate Therapeutics Inc.

Phase 2 Active not recruiting
350 enrolled
BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT04278768 2026-03-19

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Curis, Inc.

Phase 1/2 Suspended
366 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Hereditary Sensory and Autonomic Neuropathies, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡